• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Regenerative Medicine

Elutia raises $26M for drug-eluting biomatrix tech

September 19, 2023 By Sean Whooley

Elutia Logo

Elutia (Nasdaq:ELUT) announced today that it entered into a securities purchase agreement worth total proceeds of $26.2 million. The drug-eluting biomatrix company expects the private placement financing to result in initial gross proceeds of approximately $10.5 million. The full exercise of warrants would add $15.8 million to reach a total of $26.2 million. Silver Spring, […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Implants, Regenerative Medicine, Stem Cells Tagged With: Elutia

DiogenX raises $30M for regenerative diabetes treatment

May 12, 2023 By Sean Whooley

DiogenX logo-fpng

DiogenX announced that it completed a $30 million Series A financing round to support its regenerating insulin-producing beta cells. Marseille, France-based DiogenX aims to use the funds to advance its lead drug candidate into clinical development. The company designed the disease-modifying, recombinant protein to treat patients with type 1 diabetes. It modulates the Wnt/β-catenin signalling […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Regenerative Medicine Tagged With: DiogenX

Novo Nordisk, Aspect Biosystems ink $75M deal for diabetes treatments

April 12, 2023 By Sean Whooley

Novo Nordisk Aspect Biosystems logos

Aspect Biosystems and Novo Nordisk today announced a collaboration, development and license agreement around diabetes and obesity treatments. The agreement focuses on bioprinted tissue therapeutics designed to replace, repair or supplement the body’s biological functions. Novo Nordisk and Aspect aim to deliver a new class of disease-modifying treatments for diabetes and obesity. It leverages Aspect’s […]

Filed Under: Business/Financial News, Diabetes, Featured, Regenerative Medicine Tagged With: Aspect Biosystems, Novo Nordisk

Aspect Biosystems, JDRF partner to develop bioengineered tissue for type 1 diabetes

April 6, 2022 By Sean Whooley

aspect biosystems

Aspect Biosystems announced today that it entered into a partnership with the Juvenile Diabetes Research Foundation (JDRF). The partnership will support Aspect’s focus on developing a bioengineered tissue therapeutic for type 1 diabetes that will provide insulin independence and control of blood sugar without the need for chronic immune suppression. Vancouver, British Columbia-based Aspect said […]

Filed Under: Diabetes, Featured, Regenerative Medicine Tagged With: Aspect Biosystems, Juvenile Diabetes Research Foundation (JDRF)

FDA grants breakthrough nod to Zetagen’s metastatic bone cancer treatment

December 1, 2021 By Sean Whooley

Zetagen Logo

Zetagen Therapeutics announced today that it received FDA breakthrough device designation for its ZetaMet cancer treatment technology. Syracuse, New York-based Zetagen designed its ZetaMet (previously known as ZetaFuse) as a synthetic, small-molecule, inductive biologic technology for targeting and resolving metastatic bone lesions while inhibiting future tumor growth and regenerating bone. According to a news release, […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Oncology, Regenerative Medicine, Stem Cells Tagged With: FDA, Zetagen Therapeutics

MiMedx confirms shelf registration to sell $350M

September 8, 2021 By Sean Whooley

MiMedx

MiMedx (NSDQ:MDXG) announced today that its recently filed shelf registration with the SEC has become effective. Marietta, Georgia-based MiMedx last month filed the shelf registration statement on Form S-3 with the SEC with the intent to be allowed to sell up to $350 million in various types of securities over the next three years once […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Regenerative Medicine Tagged With: mimedx

MiMedx files SEC shelf registration to sell up to $350M in securities

August 27, 2021 By Sean Whooley

MiMedx

MiMedx (NSDQ:MDXG) announced today that it filed a shelf registration statement on Form S-3 with the SEC. Marietta, Ga.-based MiMedx, which develops AmnioFix, a micronized dehydrated human amnion/chorion membrane (dHACM) injection as regenerative medicine, will be allowed to sell up to $350 million in various types of securities over the next three years once the […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Regenerative Medicine Tagged With: mimedx, Securities and Exchange Commission (SEC)

Tenaya Therapeutics prices $180M IPO for targeted therapies

July 30, 2021 By Sean Whooley

Tenaya Therapeutics

Tenaya Therapeutics announced that it priced an underwritten, upsized initial public offering of common stock worth $180 million. South San Francisco-based Tenaya develops therapies for rare generic disorders and more prevalent heart conditions through gene therapy, cellular regeneration and precision medicine. The company is actively exploring different routs of administration and different infusion- and injection-based methods […]

Filed Under: Auto-injectors, Business/Financial News, Cardiovascular, Drug-Device Combinations, Featured, Funding Roundup, Initial Public Offering (IPO), Regenerative Medicine, Wall Street Beat Tagged With: Tenaya Therapeutics

Frequency Therapeutics drug shows promise in restoring hearing in small study

March 17, 2021 By Brian Buntz

Frequency Therapeutics updated logo

Frequency Therapeutics (Woburn, Mass.) recently announced data related to its experimental FX-322 drug. The small Phase 1/2 study, which was published in Otology & Neurotology, found hearing improvements in adults with age-related sensorineural hearing loss. At present, there are no FDA-approved drugs for preventing or restoring such hearing loss, although administering steroids can facilitate recovery […]

Filed Under: Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Regenerative Medicine Tagged With: age-related sensorineural hearing loss, Frequency Therapeutics, FX-322

Graphite Bio closes $150M Series B

March 16, 2021 By Sean Whooley

Graphite Bio

Graphite Bio announced that it closed an oversubscribed Series B financing round with proceeds totaling $150 million. South San Francisco-based Graphite Bio’s funding is earmarked for the expansion and advancement into the clinic of its pipeline of investigational targeted gene integration therapies with curative potential for serious diseases, according to a news release. The company […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Pharmaceuticals, Regenerative Medicine Tagged With: Graphite Bio

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 7
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS